focus -WSS

focus

author：fashion 2025-10-02 17:21:30 - browse：68

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare innovation center doesn’t save money, experts say

knowledge

WSS

Will an HIV vaccine ever be a reality?

Medicare Advantage beneficiaries sue Humana over algorithm use

The biotech scorecard for Q4: 16 stock

Hospitals owned by private equity see complications spike 25%

What STAT readers think about the FDA and patient advocacy

Health insurers' Q3 question: how much care are people getting?

leisure time

focus

The need-to-know this morning

Novavax’s money is going in the wrong direction

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medicare details structure of new drug price negotiation program

Why health records don't always know when patients are dead

Dobbs anniversary: the lost opportunity of abortion as health care

Keeping primary care docs in field isn't impossible, says AAFP CEO

Hepatitis C has a cure — but many Americans still lack access to it

Christmas in the PICU brings some surprising joy

United colonoscopy coverage change 'may cost lives,' doctors say

Experts study whether long Covid risk adds up with each reinfection

focus

Experts study whether long Covid risk adds up with each reinfection

European officials brace for rough respiratory virus season

Congress extends some pandemic preparedness programs

Experts study whether long Covid risk adds up with each reinfection

The biotech scorecard for Q4: 16 stock

IVG is promising — but it won’t replace IVF quite yet

focus

explore

knowledge

hotspot